Garuda - Garba Rujukan Digital

Sternotomy and Pericardiectomy in a Patient with Constrictive Pericarditis and Multiple Comorbidities: A Case Report Dedy Chandra Hariyono; Prima Kharisma Hayuningrat
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 6 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i6.1294

Background: Constrictive pericarditis is a serious condition that can lead to heart failure. It is characterized by a thickened and scarred pericardium, which restricts the heart's ability to fill and pump blood effectively. The condition is often caused by infections, such as tuberculosis, but can also be caused by other factors, such as radiation therapy, heart surgery, or autoimmune diseases. A pericardiectomy, a surgical procedure to remove the thickened pericardium, is the definitive treatment for constrictive pericarditis. Case presentation: This case report describes a 57-year-old male patient with constrictive pericarditis and multiple comorbidities, including recent tuberculosis, pleural effusion, ascites, and cholelithiasis. The patient presented with symptoms of shortness of breath, swollen legs, and a swollen stomach. After a thorough evaluation, including imaging studies, the diagnosis of constrictive pericarditis was confirmed. The patient underwent a sternotomy and pericardiectomy procedure, which was successful in relieving his symptoms and improving his cardiac function. Conclusion: This case report highlights the successful management of constrictive pericarditis in a patient with multiple comorbidities. The case also emphasizes the importance of early diagnosis and timely intervention in patients with constrictive pericarditis.

The Efficacy of NeuroAid™ (MLC601) in Modulating NF-κB Expression and Improving Outcomes in Traumatic Brain Injury: A Preclinical Study Dedy Chandra Hariyono; Hanis Setyono; Ida Bagus Budhi Surya Adnyana
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 6 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i6.1309

Background: Traumatic brain injury (TBI) represents a significant global health concern, leading to substantial mortality and long-term disability. The intricate pathophysiology of TBI involves primary mechanical damage followed by a cascade of secondary injury events, including neuroinflammation, apoptosis, and oxidative stress. The nuclear factor kappa B (NF-κB) signaling pathway plays a pivotal role in orchestrating the inflammatory response post-TBI and has emerged as a potential therapeutic target. This preclinical study aimed to investigate the efficacy of NeuroAid™ (MLC601), a traditional herbal medicine, in modulating NF-κB expression and improving outcomes in a rat model of TBI. Methods: This study employed a true experimental in vivo design with a post-test only control group. Male Wistar rats (n=18) were randomly divided into two groups: a control group (n=9) subjected to TBI via a weight-drop method, and an experimental group (n=9) subjected to the same TBI procedure followed by intraperitoneal administration of NeuroAid™ (MLC601) at a dose of 2.5 mg/kg body weight at 5 minutes, 8 hours, and 16 hours post-injury. NF-κB expression in brain tissue samples collected 1 hour after the final dose was assessed using immunohistochemistry and quantified by an immunoreactivity score considering both the intensity and percentage of NF-κB expression. Results: Immunohistochemical analysis revealed the presence of NF-κB expression in both the nucleus and cytoplasm of neurons in both the control and experimental groups. While the experimental group treated with NeuroAid™ (MLC601) exhibited a lower average immunoreactivity score (0.93) compared to the control group (1.29), the difference in NF-κB expression between the two groups was not statistically significant (p = 0.122). Conclusion: In this preclinical study using a Wistar rat model of TBI, the administration of NeuroAid™ (MLC601) did not result in a statistically significant reduction in NF-κB expression compared to the untreated control group. Although a trend towards lower NF-κB expression was observed in the NeuroAid™-treated group, further research with larger sample sizes, different dosages, and extended treatment durations is warranted to fully elucidate the potential therapeutic effects of NeuroAid™ (MLC601) in the management of traumatic brain injury.

Sternotomy and Pericardiectomy in a Patient with Constrictive Pericarditis and Multiple Comorbidities: A Case Report Dedy Chandra Hariyono; Prima Kharisma Hayuningrat
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 6 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i6.1294

Background: Constrictive pericarditis is a serious condition that can lead to heart failure. It is characterized by a thickened and scarred pericardium, which restricts the heart's ability to fill and pump blood effectively. The condition is often caused by infections, such as tuberculosis, but can also be caused by other factors, such as radiation therapy, heart surgery, or autoimmune diseases. A pericardiectomy, a surgical procedure to remove the thickened pericardium, is the definitive treatment for constrictive pericarditis. Case presentation: This case report describes a 57-year-old male patient with constrictive pericarditis and multiple comorbidities, including recent tuberculosis, pleural effusion, ascites, and cholelithiasis. The patient presented with symptoms of shortness of breath, swollen legs, and a swollen stomach. After a thorough evaluation, including imaging studies, the diagnosis of constrictive pericarditis was confirmed. The patient underwent a sternotomy and pericardiectomy procedure, which was successful in relieving his symptoms and improving his cardiac function. Conclusion: This case report highlights the successful management of constrictive pericarditis in a patient with multiple comorbidities. The case also emphasizes the importance of early diagnosis and timely intervention in patients with constrictive pericarditis.

The Efficacy of NeuroAid™ (MLC601) in Modulating NF-κB Expression and Improving Outcomes in Traumatic Brain Injury: A Preclinical Study Dedy Chandra Hariyono; Hanis Setyono; Ida Bagus Budhi Surya Adnyana
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 6 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i6.1309

Background: Traumatic brain injury (TBI) represents a significant global health concern, leading to substantial mortality and long-term disability. The intricate pathophysiology of TBI involves primary mechanical damage followed by a cascade of secondary injury events, including neuroinflammation, apoptosis, and oxidative stress. The nuclear factor kappa B (NF-κB) signaling pathway plays a pivotal role in orchestrating the inflammatory response post-TBI and has emerged as a potential therapeutic target. This preclinical study aimed to investigate the efficacy of NeuroAid™ (MLC601), a traditional herbal medicine, in modulating NF-κB expression and improving outcomes in a rat model of TBI. Methods: This study employed a true experimental in vivo design with a post-test only control group. Male Wistar rats (n=18) were randomly divided into two groups: a control group (n=9) subjected to TBI via a weight-drop method, and an experimental group (n=9) subjected to the same TBI procedure followed by intraperitoneal administration of NeuroAid™ (MLC601) at a dose of 2.5 mg/kg body weight at 5 minutes, 8 hours, and 16 hours post-injury. NF-κB expression in brain tissue samples collected 1 hour after the final dose was assessed using immunohistochemistry and quantified by an immunoreactivity score considering both the intensity and percentage of NF-κB expression. Results: Immunohistochemical analysis revealed the presence of NF-κB expression in both the nucleus and cytoplasm of neurons in both the control and experimental groups. While the experimental group treated with NeuroAid™ (MLC601) exhibited a lower average immunoreactivity score (0.93) compared to the control group (1.29), the difference in NF-κB expression between the two groups was not statistically significant (p = 0.122). Conclusion: In this preclinical study using a Wistar rat model of TBI, the administration of NeuroAid™ (MLC601) did not result in a statistically significant reduction in NF-κB expression compared to the untreated control group. Although a trend towards lower NF-κB expression was observed in the NeuroAid™-treated group, further research with larger sample sizes, different dosages, and extended treatment durations is warranted to fully elucidate the potential therapeutic effects of NeuroAid™ (MLC601) in the management of traumatic brain injury.

Title

Found 4 Documents
Search

Abstract

Abstract

Abstract

Abstract

Title Search

Found 4 Documents Search

Abstract

Abstract

Abstract

Abstract

Title

Found 4 Documents
Search